http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Applied DNA Announces Receipt of International Patents on its Beacon® Secure Optical Molecular Marker Technologies
-
Applied DNA Receives Kosher Certification from Orthodox Union for Qualifying Products
-
Applied DNA Sciences (APDN) Enters Multi-Year Contract with Nutrition21
-
Applied DNA Enters Dietary Supplements Market with Multi-Year Nutrition21 Contract
-
Applied DNA Sciences (APDN), LineaRx, and Takis Biotech Collaborate for Development of Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV
-
Applied DNA Sciences Subsidiary, LineaRx, and Takis Biotech Collaborate for Development of a Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV
-
Applied DNA Sciences (APDN) Announces Issuance of U.S. Patent Protecting its CertainT Platform in Man-Made Cellulosic Fibers and Materials
-
Applied DNA Announces Issuance of U.S. Patent Protecting its CertainT® Platform in Man-Made Cellulosic Fibers and Materials
-
Applied DNA Reports 2020 Fiscal First Quarter Financial Results
-
Applied DNA Schedules Fiscal 2020 First Quarter Financial Results Conference Call for Thursday, February 6, 2020 at 4:30 PM ET
-
Applied DNA Announces Issuance of U.S. Patent Protecting its CertainT® Platform in Man-Made Cellulosic Fibers and Materials
-
Applied DNA Sciences (APDN) Subsidiary LineaRx Signs Licensing Agreement with LifeSensors
-
Applied DNA Subsidiary, LineaRx, Inc., Signs Licensing Agreement with LifeSensors, Inc.
-
Applied DNA to Hold Investment Community Meetings During the JP Morgan 38th Annual Healthcare Conference and Present at the Biotech Showcase 2020
-
Colorcon, Inc. Launches On-Dose Authentication Platform From Applied DNA Sciences
-
Applied DNA Reports 2019 Year End and Fiscal Fourth Quarter Financial Results
-
Applied DNA and Old Port Oil to Conduct First Pilot to Tag CBD Oil
-
Applied DNA Sciences and Reliance Industries Sign MOU to Incorporate CertainT Forensic Traceability Into R|Elan Fabric and Recron GreenGold® Recycled Polyester Fiber and Filament
-
Applied DNA Schedules Fiscal 2019 Fourth Quarter Financial Results Conference Call for Thursday, December 12, 2019 at 4:30 PM ET
-
Applied DNA Sciences (APDN) Reports Pact with TYME Technologies for Functional Invasive Circulating Tumor Cell Assay Services in Pancreatic Cancer Trial
-
Applied DNA Sciences Subsidiary LineaRx Signs Agreement with TYME Technologies for Functional Invasive Circulating Tumor Cell Assay Services in Pancreatic Cancer Trial
-
Applied DNA Sciences Regains Compliance with Nasdaq Listing Standards
-
Applied DNA Sciences Reports 14 Development Customers for its Linear DNA Manufacturing Platform
-
Applied DNA Sciences Announces Closing of Upsized $12.0 Million Underwritten Public Offering
-
Applied DNA Sciences (APDN) to Offer 2.285M Shares with Warrants at $5.25
-
Applied DNA Sciences Announces Pricing of Upsized $12.0 Million Underwritten Public Offering
-
Successful DNA Tagging of Leather at One of the World’s Largest Tanneries
-
Applied DNA Sciences (APDN) Names Scott L. Anchin to Board
-
Applied DNA Sciences Announces Appointment of Scott L. Anchin to Board of Directors
-
Applied DNA Sciences Announces 1-For-40 Reverse Stock Split
-
Applied DNA Sciences (APDN) Receives Notice of Allowance on Patent Protecting its CertainT Platform in Cellulosic Fibers and Materials
-
Applied DNA Receives Notice of Allowance on Patent Protecting its CertainT® Platform in Cellulosic Fibers and Materials
-
Applied DNA Partners with Molecular Isotope Technologies to Elevate CertainT® for Brand Assurance and Provenance
-
Molecular Tagging of Pharmaceutical Excipients Utilizing Applied DNA’s Technology Published in Peer-Reviewed Journal
-
Applied DNA Sciences (APDN) Receives Extension from Nasdaq to Comply with Criteria for Continued Listing
-
Applied DNA Receives Extension from Nasdaq
-
LineaRx’s iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer Trial
-
Applied DNA Sciences (APDN) Secures $1M Order to Supply SigNature T Molecular Taggant for 2019-2020 Cotton Harvest Season
-
Applied DNA Receives $1 Million Order to Supply SigNature® T Molecular Taggant for 2019-2020 Cotton Harvest Season
-
Applied DNA Sciences (APDN) Announces LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction
-
LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction
-
Applied DNA Extends Textiles Business to Include Global Down and Feather Supply Chain in Partnership with Industry Leader Navarpluma
-
Applied DNA Reports Fiscal Third Quarter 2019 Financial Results
-
Medicare Coverage of CAR T-Cell Therapy Holds Positive Implications for LineaRx
-
Applied DNA Sciences (APDN) Subsidiary LineaRx, Inc. Acquires Intellectual Property of Vitatex Inc.
-
LineaRx Acquires Assets and Intellectual Property of Vitatex
-
Applied DNA Signs Master Services Agreement with Schreiner Group to Deliver SigNature® DNA Labels to Protect Pharmaceutical Supply Chains
-
Applied DNA Schedules Fiscal 2019 Third Quarter Financial Results Conference Call for Tuesday, August 13, 2019 at 4:30 PM ET
-
Applied DNA and TheraCann International Sign Term Sheet to Amend Licensing and Cooperation Agreement
-
Applied DNA Raises $1.5 Million In Secured Convertible Notes

